Conditions: HCV Infection
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 33
Healthy volunteers: yes

Brief summary:
The primary objective of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of a single dose of voxilaprevir (formerly GS-9857) in participants with normal hepatic function, moderate hepatic impairment and severe hepatic impairment. Participants in the healthy control group will be matched to participants with impaired hepatic function by gender, age (± 10 years), and body mass index (± 15%).

Detailed description:

Arms:
arm 1: Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of voxilaprevir on Day 1. arm 2: Participants with severe hepatic impairment and matched healthy controls will receive a single dose of voxilaprevir on Day 1.

Interventions: intervention 1: Voxilaprevir
Intervention descriptions: intervention 1: 100 mg tablet administered orally

Protocol document: